title: Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.
abstract: A better understanding of the relationships between vaccine, immunogenicity and protection from disease would greatly facilitate vaccine development. Modified vaccinia virus Ankara expressing antigen 85A (MVA85A) is a novel tuberculosis vaccine candidate designed to enhance responses induced by BCG. Antigen-specific interferon-γ (IFN-γ) production is greatly enhanced by MVA85A, however the variability between healthy individuals is extensive. In this study we have sought to characterize the early changes in gene expression in humans following vaccination with MVA85A and relate these to long-term immunogenicity. Two days post-vaccination, MVA85A induces a strong interferon and inflammatory response. Separating volunteers into high and low responders on the basis of T cell responses to 85A peptides measured during the trial, an expansion of circulating CD4+ CD25+ Foxp3+ cells is seen in low but not high responders. Additionally, high levels of Toll-like Receptor (TLR) 1 on day of vaccination are associated with an increased response to antigen 85A. In a classification model, combined expression levels of TLR1, TICAM2 and CD14 on day of vaccination and CTLA4 and IL2Rα two days post-vaccination can classify high and low responders with over 80% accuracy. Furthermore, administering MVA85A in mice with anti-TLR2 antibodies may abrogate high responses, and neutralising antibodies to TLRs 1, 2 or 6 or HMGB1 decrease CXCL2 production during in vitro stimulation with MVA85A. HMGB1 is released into the supernatant following atimulation with MVA85A and we propose this signal may be the trigger activating the TLR pathway. This study suggests an important role for an endogenous ligand in innate sensing of MVA and demonstrates the importance of pattern recognition receptors and regulatory T cell responses in determining the magnitude of the antigen specific immune response to vaccination with MVA85A in humans.
authors.affiliation: The Jenner Institute, University of Oxford, Oxford, United Kingdom. magali.matsumiya@msdtc.ox.ac.uk
authors.forename: Magali
authors.initials: M
authors.lastname: Matsumiya
authors.forename: Elena
authors.initials: E
authors.lastname: Stylianou
authors.forename: Kristin
authors.initials: K
authors.lastname: Griffiths
authors.forename: Zoe
authors.initials: Z
authors.lastname: Lang
authors.forename: Joel
authors.initials: J
authors.lastname: Meyer
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Harris
authors.forename: Rosalind
authors.initials: R
authors.lastname: Rowland
authors.forename: Angela M
authors.initials: AM
authors.lastname: Minassian
authors.forename: Ansar A
authors.initials: AA
authors.lastname: Pathan
authors.forename: Helen
authors.initials: H
authors.lastname: Fletcher
authors.forename: Helen
authors.initials: H
authors.lastname: McShane
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000818:Animals; D016000:Cluster Analysis; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D005260:Female; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation; D024243:HMGB1 Protein / Q000378:metabolism*; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D018950:Lipopolysaccharide Receptors / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008875:Middle Aged; D015398:Signal Transduction; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000378:metabolism*; D051194:Toll-Like Receptor 1 / Q000378:metabolism; D051195:Toll-Like Receptor 2 / Q000378:metabolism; D051216:Toll-Like Receptor 6 / Q000378:metabolism; D051193:Toll-Like Receptors / Q000235:genetics / Q000378:metabolism*; D032581:Tuberculosis Vaccines / Q000276:immunology*; D014611:Vaccination; D019444:Vaccines, DNA; D055815:Young Adult
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D018984:Epitopes, T-Lymphocyte; D024243:HMGB1 Protein; D018950:Lipopolysaccharide Receptors; C549320:MVA 85A; C480228:TICAM2 protein, human; D051194:Toll-Like Receptor 1; D051195:Toll-Like Receptor 2; D051216:Toll-Like Receptor 6; D051193:Toll-Like Receptors; D032581:Tuberculosis Vaccines; D019444:Vaccines, DNA